Study Title: Social Inclusion and People Living with Schizophrenia survey for EU research
July 29, 2013
this survey is for THE CARERS of people living with schizophrenia. The study is part of a range of activities that the Swiss pharmaceutical company, F. Hoffmann-La Roche, is undertaking with patient organisations. The study DOES NOT look at treatment or the effects of treatment for schizophrenia, but instead aims to identify some of the challenges faced by people who are affected by schizophrenia—particularly the challenge of being ‘socially included’ in society. The intention is to find out how healthcare policy can improve, and present this information to policymakers. Who is managing this survey? PatientView is managing this survey on behalf of Roche. PatientView is a UK research organisation that works closely with patient groups, and publicises the patient movement. Anonymity Everyone who takes part in this survey will be completely ANONYMOUS, and no IP addresses will be collected by the survey managers.
The survey results will be presented to national and EU policy makers at the European Health Forum Gastein in October. Roche hopes that the feedback gained from policy makers in the session will ensure that the research provides not only an understanding of the experiences of those affected by schizophrenia and their carers, but also an understanding of how healthcare policy can improve. The survey,which is owned by Roche, was drafted with the help of a steering committee made up of a range of mental health patient groups, carer groups and policy stakeholders. Roche believes that healthcare policy and services should take social inclusion into account and is collaborating with a wide variety of groups and organisations that share the same view in order to raise awareness of the benefits of social inclusion for those affected by schizophrenia and their carers.